Pacritinib, a dual JAK2 and FLT3 inhibitor has showed significant promise in early phase trials with limited haematologic toxicity and is currently in Phase III clinical trials for myeloproliferative disorders [85,86]. The gene discussed is JAK2; the disease is myeloproliferative disorder.